Sign in with Google. Opens in new tab
bullish

SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance

273 Views24 Jun 2025 00:30
​SK Bioscience initiates global Phase 3 trial of PCV21 vaccine. IDT Biologika shows revenue growth in 1Q25, on track to meet 2025 guidance. 1Q25 base business revenue increased 62% YoY.
What is covered in the Full Insight:
  • Overview of SK Bioscience's Growth Strategy
  • Current Performance and Financials
  • PCV Development Progress
  • IDT Biologika's Contribution
  • Near-term Growth Drivers and Market Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x